Exclusive rights to universal CAR technology
platform designed to target multiple antigens simultaneously,
recently expanded to include SNAP-CAR NK cells, has potential to
impact various autoimmune diseases in addition to oncology
indications.
WEXFORD,
Pa., Feb. 26, 2024 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or
"Coeptis"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, autoimmune, and infectious diseases,
today announced that it has expanded its exclusive license
agreement with the University of
Pittsburgh to include autoimmune indications as part of its
ongoing development of SNAP-CAR T and SNAP-CAR NK. This
amended agreement builds upon the original exclusive license
agreement with the University of
Pittsburgh for SNAP-CAR T Cells, a "universal" CAR T
technology platform designed to target multiple antigens
simultaneously and potentially address a range of hematologic and
solid tumors, and a recent amendment to the agreement for SNAP-CAR
NK, an allogeneic natural killer (NK) cell therapy platform.
Autoimmune diseases, including systemic lupus erythematosus,
rheumatoid arthritis, and multiple sclerosis, are known to result
from autoreactive B cells. Recent research, including a paper just
published in The New England Journal of Medicine, suggests that
CD19-targeting chimeric antigen receptor (CAR) T cells, which have
proven to be highly efficient in B cell malignancies, can also
target autoreactive B cells that trigger autoimmune
diseases.
Research published in the peer-reviewed journal Nature
Communications demonstrated the ability of SNAP-CAR to provide
a powerful adaptor strategy for fully programmable targeting of
engineered cells to multiple antigens, including CD19. Based on
these findings, Coeptis Therapeutics plans to expand the
development of the SNAP-CAR platform to target the
multibillion-dollar autoimmune disease market in addition to
hematologic and solid tumors.
"We remain committed to developing these remarkable technologies
as treatments for various indications across oncology where there
is immense unmet need, however we also recognize the enormous
potential for these platform technologies to address and possibly
revolutionize the treatment landscape of autoimmune diseases," said
Dave Mehalick, President and CEO of
Coeptis Therapeutics. "Our SNAP-CAR technologies have the potential
to position us at the forefront of next-generation autoimmune
directed therapies targeting multiple antigens through
combinatorial use of different adaptors."
"We are again excited to expand our license with Coeptis," said
Jason Lohmueller, Ph.D., Assistant
Professor of Surgery and Immunology in the Division of Surgical
Oncology Research, University of
Pittsburgh. "Leveraging the universal SNAP-CAR technology,
may bring multiple exciting and revolutionary treatments modalities
to the clinic for diverse indications in oncology and autoimmune
disease, benefiting patients and the entire healthcare
industry."
According American Autoimmune Related Disease Association, there
are more than 100 autoimmune diseases impacting 1 in every 5
Americans, 75% of whom are women. These diseases are among the top
10 causes of death in America, causing great pain and suffering,
with significant socioeconomic impact as well. Globally, the
treatment market is forecasted to grow from $7.68 billion in 2024 to $12.64 in 2028, to according to The Business
Research Company.
About Coeptis Therapeutics Holdings, Inc.
Coeptis
Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer,
autoimmune, and infectious diseases that have the potential to
disrupt conventional treatment paradigms and improve patient
outcomes. Coeptis' product portfolio and rights are highlighted by
assets licensed from Deverra Therapeutics, including an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Additionally,
Coeptis is developing a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR™ cell therapy and
companion diagnostic platforms, which Coeptis is
developing with VyGen-Bio and leading medical researchers at
the Karolinska Institutet. Coeptis' business model is designed
around maximizing the value of its current product portfolio and
rights through in-license agreements, out-license agreements and
co-development relationships, as well as entering into strategic
partnerships to expand its product rights and offerings,
specifically those targeting cancer and infectious diseases. The
Company is headquartered in Wexford, PA. For more information
on Coeptis visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the risk that the integration of the Deverra
licensed assets will disrupt current plans and operations of the
Company; (3) the inability to recognize the anticipated benefits of
the newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of
Communications
504-416-6965
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel
Kontoh-Boateng
862-213-1398
dboateng@tiberend.com
Media
David
Schemelia
609-468-9325
dschemelia@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-adds-autoimmune-indications-to-exclusive-license-agreement-with-university-of-pittsburgh-for-snap-car-t-and-snap-car-nk-302070740.html
SOURCE Coeptis Therapeutics, Inc.